GSK plc stock in focus as hepatitis B drug bepirovirsen clears key Phase 3 hurdle
GSK said on Wednesday its experimental chronic hepatitis B drug bepirovirsen met the primary endpoint in two phase III studies, putting it on track for regulatory submissions. The drugmaker said global filings are planned from the first quarter of 2026 after the B-Well 1 and B-Well 2 trials enrolled more than 1,800 patients across 29 countries. Chief Scientific Officer Tony Wood called the readout a “major advance”, and GSK said it defines a functional cure as losing a key viral protein and having no detectable virus DNA for at least 24 weeks after treatment ends. GSK
